Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hum Vaccin Immunother. 2019;15(11):2554-2560. doi: 10.1080/21645515.2019.1603985. Epub 2019 May 7.
: In South Korea, the one-dose varicella vaccine was included in the National Immunization Program for children aged 12-15 months in 2005, and the vaccine coverage reached >95%. The impact of varicella vaccination on varicella and herpes zoster (HZ) was investigated, accounting for demographic changes over time.: We calculated the crude and age-sex standardized incidence rates (IRs) and age-specific IRs of varicella and HZ from 2003 to 2015, using the National Health Information Database including approximately 50 million Koreans. The annual incidence rate ratios (IRRs) were calculated using a negative binomial regression analysis, adjusting for age and sex.: The crude varicella IR steadily declined by 67%, from 5.70/1000 to 1.87/1000 person years (IRR per year: 0.91; 95% CI 0.89-0.93), but the adjusted IRs showed a significant decline only during 2010-2015 (adjusted IRR per year: 0.90; 95% CI 0.88-0.93). The greatest decline was found in children ≤4 years of age, whereas the IR increased until 2011 and then declined afterward in children aged 5-9 years, who represented the highest incidence age group in 2013-2015. The crude HZ IR increased from 2.67/1000 to 9.80/1000 person years (IRR per year: 1.12; 95% CI 1.10-1.15), and the adjusted IR also followed the same trend. A similar increasing trend was observed before and after universal vaccination.: One-dose varicella vaccination was moderately effective in preventing varicella, but this strategy was insufficient to interrupt varicella transmission in children. Furthermore, the HZ incidence dramatically increased over this decade. The current vaccination strategy against varicella-zoster disease should be reconsidered.
: 在韩国,2005 年将一剂水痘疫苗纳入了 12-15 月龄儿童的国家免疫规划,疫苗覆盖率达到>95%。本研究旨在评估水痘疫苗接种对水痘和带状疱疹(herpes zoster,HZ)的影响,同时考虑了随时间变化的人口统计学因素。: 我们利用包含约 5000 万韩国人的国家健康信息数据库,计算了 2003 年至 2015 年水痘和 HZ 的粗发病率和年龄性别标准化发病率(incidence rate,IR)以及年龄特异性 IR。采用负二项回归分析计算发病率比(incidence rate ratio,IRR),并按年龄和性别进行校正。: 水痘的粗发病率持续下降 67%,从 5.70/1000 人年降至 1.87/1000 人年(每年发病率比:0.91;95%CI 0.89-0.93),但仅在 2010-2015 年调整后的发病率呈显著下降(每年调整后发病率比:0.90;95%CI 0.88-0.93)。发病率下降最大的是≤4 岁儿童,而 5-9 岁儿童的发病率在 2011 年之前增加,随后在 2013-2015 年降至最低。HZ 的粗发病率从 2.67/1000 人年增至 9.80/1000 人年(每年发病率比:1.12;95%CI 1.10-1.15),调整后的发病率也呈现相同趋势。在普遍接种水痘疫苗前后均观察到类似的上升趋势。: 一剂水痘疫苗在预防水痘方面具有中等效力,但该策略不足以阻断儿童中的水痘传播。此外,在过去十年中,HZ 的发病率显著增加。目前针对水痘-带状疱疹疾病的疫苗接种策略应重新考虑。